Anti-aging interventions affect lifespan variability in sex, strain, diet and drug dependent fashion by Bartke, A. et al.




                                                                                                                                            Research Paper 
www.aging-us.com 4066 AGING 
INTRODUCTION 
 
In studies of aging, changes in the length of life are 
usually analyzed by comparing average (mean) or 
median longevity. Frequently, some estimate of 
maximal longevity is also considered. While values of 
the standard deviations or standard errors of the mean 
are routinely reported, the distribution of individual age 
at death is rarely analyzed or discussed. This contrasts 
with the recent interest in analyzing the distribution of 
biomarkers of aging using the statistical distance 
measure [1] to estimate the level of physiological 
dysregulation and to relate it to resilience and 
robustness during aging [2]. 
 
In a recent publication based on analysis of demographic 
data, Van Raalte and her colleagues reported that socio-
economic status influences not only the mean longevity 
but also the variability of human life-span [3]. Using an 
example of Finnish women, these investigators showed 
that reduced mean longevity of less educated and less 
affluent people is associated with greater variability of 
life-span. The inverse relationship of life expectancy and 
life-span variation was seen also in other human 
populations [3]. The practical implication of these 
findings is that for both the individuals and the health 
care systems it is more difficult to predict the age at 
death of the less privileged people than of the more 
privileged strata or for the entire population. 
 
Because of the potential significance of this relationship 
for the analysis of mortality data and physiological 
biomarkers in studies of aging as well as for various 
public health considerations, we thought that it would 
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It was recently reported that socio-economic factors related differences in human life expectancy are 
associated with differences in the variance of age at death. To determine whether anti-aging interventions also 
alter the variance of longevity, we have analyzed data from mice subjected to treatment with drugs that affect 
aging or to calorie restriction and from long-lived mutant mice. The relationship of changes in longevity and in 
longevity variance was found to depend on sex and treatment and apparently also on strain. Increased 
longevity of male mice treated with effective anti-aging drugs was accompanied by reduced variance of age at 
death and apparent reduction of early life mortality. Life extension induced by growth-hormone related 
mutations and calorie restriction tended to increase longevity variance in females only. We conclude that 
impact of anti-aging interventions on the variance of age at death and distribution of individual lifespans in 
laboratory mice is treatment-dependent and sexually dimorphic. 
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be of interest to determine whether interventions known 
to extend the average (or the average and the maximal) 
longevity of experimental animals have any effect on 
the variability of life-span. We hypothesized that 
extension of longevity by genetic, dietary or 
pharmacological means leads to reduction of life-span 
variability. However, inspection of data from the 
National Institute of Aging Interventions Testing 
Program (ITP) [4] and from our studies of the 
interactions of murine longevity genes with calorie 
restriction (CR) [5-7] indicated that reciprocal changes 
of longevity and its variability are not consistently 
observed. This suggested that our hypothesis would 
most likely need to be rejected and brought up a new 
question, namely, what factors influence variability of 
the lifespan. Here we report results of a study aimed at 
analyzing the effects of sex, strain, life-extending 





When the longevity of the mice in the ITP dataset was 
correlated to the variance in longevity, a strong decrease 
in variance with increasing longevity was observed. 
Skewness also decreased, while kurtosis, i.e., non-
flatness, increased (Table 1). However, when gender 
was included in these relationships, we found that it 
strongly affected the results (Fig. 1; Table 2).  
 
The most striking finding was that the variance of 
longevity is strongly sexually dimorphic (Fig. 1) (Table 
2: 𝛘𝛘² = 20.47; df = 1; p < 0.001). In females the variance 
did not decrease with the increased longevity (Table 2: 
𝛘𝛘² = 0.95; df = 1; p =0.329), while that in males did (𝛘𝛘² 
= 20.47; df = 1; p < 0.001). The skewness decreased (𝛘𝛘² 
= 33.74; df = 1; P < 0.001), equally in both female and 
males (𝛘𝛘² = 0.35; df = 1; p = 0.556). Kurtosis increased 
slightly (𝛘𝛘² = 4.51; df = 1; p = 0.034), but was 
 
 
Figure 1. Relationship between longevity and variance (a), 
skewness (b), and kurtosis (c). Females: red circles; males: blue 
circles; filled circles: treated; and unfilled circles; untreated. 
 
Table 1. Estimates of the regression coefficients of the fitted line of longevity against variance, skewness 
and kurtosis.  
 Estimate SE t-value 
df 𝛘𝛘² (LRT) p-value  
Variance (MAD) -0.425 0.047 -9.125 1 71.57 <0.001  
Skewness -0.442 0.047 -9.472 1 79.98 <0.001  
Kurtosis 0.325 0.049 6.681 1 42.19 <0.001  
In each test group, longevity is measured as the median age at death, variance as the Median Absolute Deviation (MAD) 
of age at death, skewness as the skewness of age at death, and kurtosis as the kurtosis of age at death. Estimate, 
standard error (SE) and t-value are from linear mixed models with research site as random effect variable. 𝛘𝛘² and p-
value are from a Likelihood Ratio Test (LRT) where the model with the independent variable is compared to the model 
without that variable. 
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significantly lower in males than females (𝛘𝛘² = 29.16; df 
= 1; p < 0.001). 
 
A graphic representation of the variance in longevity of 
control mice vs mice treated with effective anti-aging 
compounds showed that, apart from the effect of the 
compounds on median longevity, they mainly seemed to 
decrease early death in males (Fig. 2). 
The dataset of the longevity genes/CR studies showed 
no overall correlation between the median longevity per 
test group and the variance in longevity, measured as 
MAD per test group (𝛘𝛘² = 0.25; df = 1; p = 0.617). 
When gender was taken into consideration and the 
studies were split according to effect of diet, genotype, 
or diet plus genotype, it was found that when mice had 
longevity extending genotypes and were treated with 
Table 2. Estimates of contrasts of models of longevity against variance, skewness and kurtosis, including 
gender and the interaction between gender and independent variables.  
  Estimate SE t-value df 𝛘𝛘² (LRT) p-value  
Variance (MAD) Intercept (F) -0.623 0.067 -9.288     
 Gender (M) 1.035 0.089 11.659 
1 115.83 <0.001  
 Median age 0.071 0.072 0.978 
1 0.95 0.329  
 Interaction Gender x Median -0.437 0.091 -4.782 
1 20.47 <0.001  
Skewness Intercept (F) 0.068 0.083 0.822     
 Gender (M) -0.106 0.104 -1.024 
1 1.03 0.310  
 Median age -0.505 0.084 -5.986 
1 33.74 <0.001  
 Interaction Gender x Median 0.064 0.107 0.591 
1 0.35 0.556  
Kurtosis Intercept (F) 0.299 0.077 3.887     
 Gender (M) -0.579 0.105 -5.505 
1 29.16 <0.001  
 Median age 0.182 0.085 2.129 
1 4.51 0.034  
 Interaction Gender x Median 0.023 0.108 0.216 
1 0.05 0.829  
Estimate, standard error and t-value are from linear mixed models with research site as random effect variable. 𝛘𝛘² and 
p-value are from a Likelihood Ratio Test (LRT) where the model with the independent variable is compared to the model 
without that variable. 
 
 
Figure 2. Density plots of the age at death of control mice (a) and mice treated with effective anti-aging pharmaceuticals (b). Cox-
test for difference between females (solid red line) and males (dashed blue line) in survival with research site as random effect 
variable: control mice: z = 11.02, p < 0.001; treated mice: z = 6.95, p < 0.001. 
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CR, variance of females increased near statistical 
significance (𝛘𝛘² = 3.25; df = 1; p = 0.071), while in 
males this seemed not the case (Figure 3; Table 3). 
 
The graphic representation of the variance in longevity 
of control mice vs long-lived mutant mice treated with 
CR showed that, apart from the life extending effect of 
the treatment on median longevity, the gender 
difference in longevity was due predominantly to some 




Results of the present study indicate that interventions 
which extend longevity in laboratory mice can also alter 
the distribution and the variance of age at death. The 
presence, the magnitude, and apparently also the 
direction of these changes depends on the sex of the 
animals and the nature of the interventions. In the large 
data set from the ITP studies, increased longevity was 
associated with reduced variance in males (p<0.001) but 
not in females. Moreover, distribution of the data 
suggested a possible trend for variance in female data 
changing in the opposite direction (Fig 1). In long-lived 
mice with GH-related mutations, subjected to CR, 
variance was not related to longevity in males, but 
seemed to increase with longevity in females (p=0.071).  
 
Sexual dimorphism in the responses to longevity-
extending interventions is not unexpected and our 
findings show that the relationship of the distribution of 
individual age at death data to the average life span of 
the population is also sex-dependent. Thus, the present 
results add to the growing body of evidence that various 
aspects of aging, including longevity, as well as 
responses to various anti-aging interventions cannot be 
predicted from data obtained in individuals of different 
sex [8].  
 
The reciprocal relationship of human longevity and its 
variablitiy that Van Raalte, et al. [3] found in various 
data sets were from segments of the same population 
separated on the basis of income, educational 
attainment, and/or type of employment. The biological 
basis of the well-documented impact of socio-economic 
factors on human aging is believed to include 
differences in diet, health-related behaviors, and access 
to as well as quality of health care, although 
significance of the latter factors in Finland and other 
countries with excellent health care systems is 
presumably small or absent. 
 
Since animals in each of the four examined cohorts 
were genetically heterogeneous and three of the four 
cohorts were relatively small, this study does not allow 
any firm conclusion on the possible differences between 
strains. Studies including large genetically distinct 
populations, different inbred strains and preferably also 
their crosses would be needed to address this issue.  
Table 3. Estimates of contrasts of models of longevity with variance including gender and the interaction 
between gender and independent variables; CR, life extending mutations, or both.  
  Estimate SE t-value 
df 𝛘𝛘² (LRT) p-value  
Diet Intercept (F) 0.375 0.442 0.850     
 Gender (M) -0.756 0.625 -1.210 
1 2.02 0.156  
 Median age -0.032 0.433 -0.074 
1 0.01 0.928  
 Interaction Gender x Median -0.058 0.659 -0.088 
 0.01 0.914  
Genotype Intercept (F) 0.298 0.494 0.603     
 Gender (M) -0.576 0.616 -0.936 
1 1.16 0.282  
 Median age -0.192 0.457 -0.420 
1 0.25 0.616  
 Interaction Gender x Median 0.124 0.644 0.192 
1 0.07 0.798  
Diet+Gen. Intercept (F) 0.379 0.450 0.843     
 Gender (M) -0.810 0.454 -1.787 
1 3.83 0.050  
 Median age 0.567 0.347 1.636 
1 3.25 0.071  
 Interaction Gender x Median -0.573 0.477 -1.202 
1 1.97 0.161  
Estimate, standard error and t-value are from linear mixed models with strain as random effect variable. 𝛘𝛘² and p-value 
are from a Likelihood Ratio Test (LRT) where the model with the independent variable is compared to the model 
without that variable. 
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What can be concluded from our analysis is that in 
studies of anti-aging interventions in laboratory animals 
the changes in variability of lifespan cannot be 
predicted from changes in longevity. It is interesting to 
speculate that this may be related to differences in the 
mechanisms responsible for lifespan extension by the 
various interventions. 
 
In the data sets we analyzed, there were examples of 
differences in the proportion of early deaths in females 
and males as well as in long-lived (mutant, calorie 
restricted or drug-treated) vs control (wild type, fed ad 
libitum, or untreated) animals and the slopes of survival 
curves also differed in some cases. Skewness and 
kurtosis were as expected. The differences in the 
distribution of individual lifespans may have 
contributed to the observed differences in variation. For 
example, decrease in the occurrence of early deaths 
likely contributed to longevity of drug-treated males in 
the ITP studies [9]. This and other examples of the role 
of early deaths in determining the longevity of the 
whole cohort resemble demographic findings on the 
effects of socio-economic factors in human populations 
[3]. 
 
Analysis of distribution of individual age at death 
values suggests a differential impact of the examined 
anti-aging interventions at different segments of life 
history. This, in turn, is likely related to different 
mechanisms of their actions. Significant correlation of 
extended longevity with reduced variance of individual 
death in various human populations [3] and in male 
mice from the ITP cohort (Fig 1), may have been due, 
in part, to the “ceiling effect” as longevity approaches 
the value of maximal lifespan for the species. More 
likely, it reflects greater proportion of early deaths of 
 
 
Figure 3. Effects of CR, life extending mutations or both 
on the relationship to longevity and variance in female 
and male mice. Females: red circles; males: blue circles; 




Figure 4. Density plots of the age of death of control mice (a) and mice treated with anti-aging diet as well as having anti-aging 
genotypes (b). Cox-test for difference between females (solid red) and males (dashed blue) in survival with strain as random effect 
variable: control mice: z = 0.57, p = 0.57; treated mice: z = 3.97, p < 0.001. 
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various etiologies in groups with shorter median 
lifespan. Intriguingly, trajectories of several 
physiological processes mechanistically related to aging 
are more variable in short-lived than in exceptionally 
long-lived people [10]. 
 
Regardless of the mechanisms involved, our data 
suggest that analysis of changes in the variability of 
life-spans in response to various interventions can 
provide additional information on the nature of the 
observed effects. 
 
MATERIALS AND METHODS 
 
We used data on the length of life of individual mice 
(age at death measured in days) from the ITP [4] and 
from studies conducted at Southern Illinois University 
(SIU) [5-7]. In the ITP, genetically heterogeneous (UM-
HET3) female and male mice derived from crosses of 
four inbred strains were treated with various compounds 
starting in early adulthood and continuing until they 
died or were euthanized when judged to be moribund. 
These studies were conducted in parallel at three 
collaborating institutions. Both significant extension of 
longevity and absence of effects were reported in peer-
reviewed literature [9, 11-15]. A listing of the 
compounds, their actions and the percent increase in 
median longevity of treated animals are listed in Table 4 
along with references to publications reporting 
longevity data.  
 
The effects of pharmacological anti-aging interventions 
in the ITP studies were analyzed using the data from 
treated mice with documented life extension and 
matching controls. These groups include animals treated 
with acarbose [9], aspirin [11], 17-α-estradiol [9], 
dietary glycine [15], nordihydroguaiaretic acid [9, 11], 
ProtandimTM (mixture of plant extracts) [14], or 
rapamycin [16]. Longevity variance was examined in 
relation to treatment and sex while taking into account 
differences in testing laboratories [4].  
 
A second dataset was created with individual longevity 
data of mice from three separate experiments on the 
interaction of calorie restriction (CR) with one of three 
life-extending mutations [5-7]. These experiments used 
mice with suppression of growth hormone (GH) 
signaling by a mutation interfering with differentiation 
of three types of anterior pituitary cells leading to 
hypopituitarism including GH deficiency [17, 18], 
deletion of GH releasing hormone (GHRH) gene 
leading to isolated GH deficiency [19], or deletion of 
the GH receptor (GHR) gene leading to GH resistance 
[20]. Approximately half of the animals in each 
genotype/sex group were fed ad libitum (AL), while the 
remainder were subjected to calorie restriction (CR) 
starting in early adulthood by feeding them 60 -70% of 
the amount of food consumed during the preceding 
week by age, sex, and genotype matched AL mice. The 
employed mutations were maintained on a 
heterogeneous genetic background which was different 
for each mutation and different from the genetic make-
up of the ITP mice. Each of the three mutations used in 
these studies increases longevity of both females and 
males while the effects of CR on longevity were 
mutation- and sex-dependent [5-7]. Percent increase of 
median longevity in each genotype/sex/diet group is 
listed in Table 5. 
 
Longevity variance was examined in relation to 
different groups (genotype, diet, and sex combinations). 
Interventions that were ineffective (such as CR in GHR 
Table 4. Percent increase in median lifespan due to pharmacological agents administered in the 
Interventions Testing Program. 
Drug Effects, mode of action Δ Median lifespan Citation 
  Females Males  
Acarbose 
 
Inhibitor of intestinal alpha-glocosidase 5 22 Harrison et al., 2014 
Aspirin anti-inflammatory, antithrombotic and 
antioxidant 
ns 8 Stong et al., 2008 
17 alpha-estradiol neuroprotection ns 12 Harrison et al., 2014 
Dietary glycine anti-inflammatory 4 1 Brind et al., 2018 
NDGA Antioxidant, anti-inflammatory ns 8-10 Harrison et al., 2014 
Protandim (mixture of 
plant extracts) 
Nrf activation; increase of antioxidant 
defenses 
ns 7 Strong et al., 2016 
Rapamycin Inhibitor of mTORC1 18 10 Miller et al., 2011 
Footnote: For some of the above listed drugs, additional studies were conducted using different doses and or starting 
treatment at a different age which resulted in somewhat different % extension of median life-span. 
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-/- mice) were included to account for the possibility 
that CR could alter variance without altering the 
median. 
 
We performed all statistical analysis using R software 
3.4.4 [21]. For studying the relationship between 
longevity and variance in longevity we calculated the 
median age at death of the females and males of all 
available test groups. We chose median instead of mean 
because we could not assume that the variance in 
longevity was normally distributed. For the variance in 
longevity we calculated the MAD, i.e., the Median 
Absolute Deviation, a robust metric fit for non-normal 
distributions [22]. Median, MAD, skewness, and 
kurtosis were all calculated with the function 
describeBy() of the package psych [23]. For testing the 
relationships between longevity and variance, skewness 
and kurtosis, the function lmer() of the package lme4 
[24] for linear mixed-effect models were applied, 
combined with the drop1() function for the Likelihood 
Ratio Test (LRT). For testing the difference in survival 
between females and males, the Cox test for mixed 
effects was used, i.e., the function foxme() of the 
package foxme [25]. As random effect variable, the 
research site was included in all analyses of the ITP data 
and the strain in all analyses of the SIU (mutations/CR) 
data. The graphs were constructed using scatterplot() 
and densityPlot(), both of the package car [26]. We 
preferred density plots over Kaplan-Meier survival 
plots, because they show more clearly where the 
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